Skip to main content

Market Overview

Novo Nordisk: Q4 Earnings Insights



Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of $0.64.

Revenue of $5,142,000,000 up by 5.74% year over year, which missed the estimate of $5,350,000,000.

Looking Ahead

Novo Nordisk hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Feb 03, 2021

Time: 07:00 AM

ET Webcast URL:

Price Action

52-week high: $73.92

Company's 52-week low was at $49.24

Price action over last quarter: Up 9.13%

Company Profile

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.


Related Articles (NVO)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at